{"ticker": {"uuid": "536f3d46-94f4-4a15-87b0-33746efc4669", "symbol": "HALO", "name": "Halozyme Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Is Halozyme ENHANZE Deal Reshaping Subcutaneous Antibody Delivery For Incyte\u2019s Pipeline Strategy (INCY)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-21T20:26:04+00:00", "published_display": "21 Jul 2026 20:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Halozyme\u2019s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/did-halozyme-halo-incyte-enhanze-151039541.html", "source_name": "Simply Wall St.", "published_at": "2026-07-21T15:10:39+00:00", "published_display": "21 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com", "summary": "Benchmark reiterated its Buy rating and $90 price target for Halozyme Therapeutics following the company's licensing agreement with Incyte Pharmaceuticals. The deal involves Halozyme's Enhanze drug development technology to create subcutaneous formulations of Incyte's INCA033989.", "url": "https://ca.investing.com/news/stock-market-news/benchmark-reiterates-halozyme-stock-buy-rating-on-incyte-deal-93CH-4744464", "source_name": "Investing.com Canada", "published_at": "2026-07-21T14:10:37", "published_display": "21 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Incyte stock rating on Halozyme deal By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOSktKc1Y1WDI2MmUyam9OUnJZS3Jld1BodUxMR1pnZGtUN1JRUi1IeGFHeS1HTEFhOGQ1US1oczExcU02amVfZE00TmtxYVl6NWI1U0pDRkktV2lIdjZvaVRGdUx2d1dWUFdpTFhCNTZVeEhWRFFqaUdrY0FHdUdvbDlHNTlVM0NweUZrUkRjYXBOZlVmYndrOVQ1cUFjczl3WWVHTnh4T1RrT1RSaUhzaDJJbzFOYmhiUktIUzM1VQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-21T11:40:50+00:00", "published_display": "21 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme and Incyte sign licence agreement for INCA033989 formulations", "summary": "", "url": "https://finance.yahoo.com/m/471ceb81-68b7-373c-a767-a5d3eef4153b/halozyme-and-incyte-sign.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-21T09:31:32+00:00", "published_display": "21 Jul 2026 09:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued", "summary": "Halozyme Therapeutics recently partnered with Incyte, using its Enhanze technology for subcutaneous formulations. Despite a 12.46% share price increase over 30 days and long-term gains, the stock appears undervalued, with analysts estimating a fair value of $83.90 compared to its", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/halozyme-therapeutics-halo-lands-incyte-deal-on-a-valuation", "source_name": "Simply Wall Street", "published_at": "2026-07-21T10:10:37", "published_display": "21 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme (HALO) Partners with Incyte to Advance Drug Delivery Te", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPMmdtYk9PR2xieG9MdlRtcHJoZ3gtRHhIR1pMY0tuYXN1R1RsLTRCQ2dtOGRXYnBKSWVCc3JOaXRwZmJfNEpIdFdxTnp5cmMtaHM5Sk1JeU1fSy1NWXVYbUtySEFrSmZLNnNXNVVfR210Q1VLb3NCSjZXTENKVy0yVWM5Wi15TXNoc3E5M0I4R3RZRXlqOWJlT1hyTTRrY0l1VWNWdWRxdFp2TnBvNzRGb2Y5ZDFhQTQtbWxZZFdfcXBIOXZuVER6QWc4bnF0YVhBZll6MEFoLTRWamw3MTJJaWQ3MA?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-20T19:58:47+00:00", "published_display": "20 Jul 2026 19:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development", "summary": "Halozyme Therapeutics has entered into a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using its ENHANZE drug delivery technology. This agreement provides Halozyme with an upfront payment, potential milestone payments, a", "url": "https://finance.yahoo.com/healthcare/articles/halozyme-signs-enhanze-collaboration-incyte-150243781.html", "source_name": "Market source", "published_at": "2026-07-20T14:41:25", "published_display": "20 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Secures Global Deal with Incyte for Innovative Drug Delivery", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPeU1FM1JLMi05MExiTlY1YXJhWlhWSEg4VFNrcko1b3FoTm9LM2ZDV1UwUXpvdDVKM1hqVEt6Smh6Vlg3c2RGRnU1SmRkdnJWSHgzWi1BN1dDTFpCZUFBbUZYdXpwQnRoQVdVTE5qenBaMkRJQWR2SURVdUFEdHc0azR1aDRZR3B3ZFlkM05kbFh4amppZi1iX01nUkwxdkZHOV9FZGY2Szl6TEZwemVfVkJ5MWR6Z2tUS19vc3B2X2dGcWpsYlBIZGZBdXhYRFlTeXY4X0hPbFI5Uk1BQ1gwNENZNDg4NzdITlVlZEhDTkhVVFJNenJLYmN3?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-20T13:05:06+00:00", "published_display": "20 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics, Incyte Sign Deal to Develop Subcutaneous Formulations of Blood Cancer Drug", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/halozyme-therapeutics-incyte-sign-deal-124534011.html", "source_name": "MT Newswires", "published_at": "2026-07-20T12:45:34+00:00", "published_display": "20 Jul 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme partners with Incyte on drug delivery technology By Investing.com", "summary": "Halozyme Therapeutics Inc. has announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE drug delivery technology. Halozyme will receive an upfront payment and is eligible for additional mileston", "url": "https://ca.investing.com/news/stock-market-news/halozyme-partners-with-incyte-on-drug-delivery-technology-93CH-4741809", "source_name": "Investing.com Canada", "published_at": "2026-07-20T12:41:25", "published_display": "20 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE\u00ae Technology", "summary": "Halozyme Therapeutics, Inc. (Nasdaq: HALO) has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE\u00ae drug delivery technology. This collaboration aims to improve the treatm", "url": "https://www.prnewswire.com/news-releases/halozyme-announces-global-collaboration-and-license-agreement-with-incyte-to-support-the-development-of-subcutaneous-formulations-of-inca033989-using-its-enhanze-technology-302829283.html", "source_name": "PR Newswire", "published_at": "2026-07-20T11:41:25", "published_display": "20 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to HALO Trends in Macro Strategies", "summary": "This article from Stock Traders Daily discusses technical reactions to HALO trends in macro strategies, focusing on Halozyme Therapeutics Inc. (NASDAQ: HALO). It highlights conflicting sentiment across different time horizons, suggesting choppy market conditions for the stock. Th", "url": "https://news.stocktradersdaily.com/news_release/23/Technical_Reactions_to_HALO_Trends_in_Macro_Strategies_071926041202_1784448722.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-19T04:13:10", "published_display": "19 Jul 2026 04:13", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival", "summary": "Halozyme Therapeutics (HALO) saw a positive impact from a partner trial for Darzalex Faspro, which uses Halozyme's ENHANZE technology. The trial reported significant survival benefits for multiple myeloma patients, highlighting the value of ENHANZE in improving established cancer", "url": "https://www.sahmcapital.com/news/content/halozyme-therapeutics-halo-gets-a-lift-as-darzalex-faspro-trial-improves-survival-2026-07-18", "source_name": "Sahm", "published_at": "2026-07-18T19:41:25", "published_display": "18 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Halozyme Therapeutics, Inc. Stocks", "summary": "This article lists various ETFs that include Halozyme Therapeutics, Inc. (HALO) stocks in their portfolios. The ETFs are sorted by their market value and provide details like weight, issuer, management style, expense ratio, and AUM, making it easier for investors to find opportun", "url": "https://www.tradingview.com/symbols/BOATS-HALO/etfs/", "source_name": "TradingView", "published_at": "2026-07-17T17:41:21", "published_display": "17 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxORmlQeURzMHhqdUNaSHBqMElOQ09hTnpGbTQ2N212dldMRlFib3IwaERwNUdFOWY1MUdUQ3NTUkFCWGhvb01WdXhFWGRZX0tZUi1jcHNfWlFTYWcyNUlsc1R6YnE0Q3JGSURxcXNNbVBrZ2k3YjVaXzJ1YzZXOW56WXZVeDF4ZENQMnhzYS1ZdmI2cU5QSnd6YTdYWUdBXzAyRkhVbGh5RDE?oc=5", "source_name": "Market source", "published_at": "2026-07-15T13:46:28+00:00", "published_display": "15 Jul 2026 13:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HALO5387960 Bond Risk Profile", "summary": "This article provides a risk profile for the Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027 bond, identified as HALO5387960. It offers an overview of the bond's coupon, redemption details, and crucial risk assessment metrics. The content highlights credit risk, security level, inf", "url": "https://www.tradingview.com/symbols/FINRA-HALO5387960/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-15T06:12:46", "published_display": "15 Jul 2026 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HALO5387960 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides a coupon profile for the HALO5387960 bond, issued by Halozyme Therapeutics, Inc., detailing its interest rate and payment schedule. The bond has a current coupon rate of 0.25%, with the next payment planned for September 1, 2026. The article highlights the i", "url": "https://www.tradingview.com/symbols/FINRA-HALO5387960/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-14T22:40:49", "published_display": "14 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HALO5387960 Bond Profile \u2014 Key Metrics", "summary": "This article provides a bond profile for Halozyme Therapeutics, Inc.'s bond HALO5387960, detailing key metrics such as its 0.25% coupon rate and March 1, 2027 maturity date. It also includes information about the company, Halozyme Therapeutics, Inc., identifying it as a biopharma", "url": "https://www.tradingview.com/symbols/FINRA-HALO5387960/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T14:41:20", "published_display": "14 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 10% Upside Potential in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOcWVscy1sdVQ1SnZkbGpBMk5VbTkwczFmYTRqWmxaWkhsYkJHczlKYkcxYloweEpJa3Bxay1xMXRQUndmSS1feGQ0a05rUlcwazdjdTN2QU1zUTNGZ0hoU1JwNW15UnkwYzBtajVCb29SZ3ZtLWlvdUlRMEw4RnVodklVNWtqcm5YNnR3OFRMYXVxSnhjQ1VUU2hhbGotR1BsWVpnaFg0WXQ2LTJtTklrZnM1V2o2RERfcjE3VDA1Ynp2UEpkMzAyM0tSak5wYm5qVTIxOVZsV1J0am92LTdzMjdEN0o?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:18:25+00:00", "published_display": "13 Jul 2026 09:18", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Halozyme Therapeutics (HALO) Proxy filing Summary", "summary": "Halozyme Therapeutics (HALO) has released a summary of its proxy filing for the 2026 Annual Meeting, scheduled virtually for May 5, 2026. Key proposals include the election of two Class I directors, an advisory \"say-on-pay\" vote for executive compensation, and the ratification of", "url": "https://quartr.com/events/halozyme-therapeutics-halo-proxy-filing_ofWrSbzj", "source_name": "Quartr", "published_at": "2026-07-12T04:40:26", "published_display": "12 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) AGM 2026 Summary", "summary": "This article summarizes Halozyme Therapeutics' (HALO) 2026 Annual General Meeting (AGM), detailing the election of Class I directors, approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor. It also provides a brief overview of recent ", "url": "https://quartr.com/events/halozyme-therapeutics-halo-agm-2026_ofWrSfzP", "source_name": "Quartr", "published_at": "2026-07-11T18:11:32", "published_display": "11 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Q1 2026 earnings summary", "summary": "Halozyme Therapeutics reported a strong Q1 2026 with total revenue increasing by 42% year-over-year to $376.7 million and net income up 27% to $150 million. The company announced a new $1 billion share repurchase program and expanded its ENHANZE and Hypercon platforms through new", "url": "https://quartr.com/events/halozyme-therapeutics-inc-halo-q1-2026_ofWrSUIm", "source_name": "Quartr", "published_at": "2026-07-11T16:41:02", "published_display": "11 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Q1 2025 earnings summary", "summary": "Halozyme Therapeutics reported a strong Q1 2025, achieving 35% year-over-year revenue growth to $265 million and a 54% increase in net income to $118 million, driven by blockbuster products and new growth catalysts. The company also announced a $250 million share repurchase progr", "url": "https://quartr.com/events/halozyme-therapeutics-inc-halo-q1-2025_ofWrCl7j", "source_name": "Quartr", "published_at": "2026-07-11T08:39:25", "published_display": "11 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $83.44, Implies 6% Upside", "summary": "Halozyme Therapeutics, Inc.'s average price target has been reduced from $83.9 to $83.44 by 9 analysts, with forecasts ranging from $57 to $96 per share. This new target implies a potential upside of approximately 6% based on the July 9 closing price. Despite the slight reduction", "url": "https://www.tradingview.com/news/tradingview:633e185273125:0-halozyme-therapeutics-inc-stock-12-month-price-target-cut-to-83-44-implies-6-upside/", "source_name": "TradingView", "published_at": "2026-07-10T07:11:10", "published_display": "10 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2 Reasons to Like HALO and 1 to Stay Skeptical", "summary": "Halozyme Therapeutics (HALO) shows strong potential with impressive annualized revenue growth of 35.4% over five years and an excellent free cash flow margin averaging 46.2%. However, its adjusted operating margin significantly decreased by 35.1 percentage points in the last five", "url": "https://www.tradingview.com/news/stockstory:8d8c360f8094b:0-2-reasons-to-like-halo-and-1-to-stay-skeptical/", "source_name": "TradingView", "published_at": "2026-07-10T04:11:11", "published_display": "10 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Halozyme\u2019s Leadership Shake-Up Around Drug Delivery At Halozyme Therapeutics (HALO) Has Changed Its Investment Story", "summary": "Halozyme Therapeutics recently restructured its leadership, appointing David Ramsay as President of Drug Delivery and announcing the departure of COO Cortney Caudill. This move emphasizes the company's focus on its drug delivery franchise, particularly the ENHANZE platform, and a", "url": "https://www.sahmcapital.com/news/content/how-halozymes-leadership-shake-up-around-drug-delivery-at-halozyme-therapeutics-halo-has-changed-its-investment-story-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T04:10:26", "published_display": "10 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Halozyme Therapeutics Inc For: 9 July By Investing.com", "summary": "This article reports on the filing of Form 4 by Halozyme Therapeutics Inc., specifically for July 9. The headline and content confirm the filing, indicating standard regulatory disclosure within the financial markets. The brief notice was published on Investing.com.", "url": "https://za.investing.com/news/stock-market-news/form-4-halozyme-therapeutics-inc-for-9-july-93CH-4363437", "source_name": "Investing.com South Africa", "published_at": "2026-07-09T23:26:00", "published_display": "09 Jul 2026 23:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme president & CEO Helen Torley sells $153,390 in stock", "summary": "Helen Torley, President and CEO of Halozyme Therapeutics, Inc. (NASDAQ:HALO), sold 1,923 shares for $153,390 after exercising stock options. These transactions were conducted under a pre-arranged trading plan, and Torley now directly owns 767,780 shares. The company has also seen", "url": "https://www.investing.com/news/insider-trading-news/halozyme-president--ceo-helen-torley-sells-153390-in-stock-93CH-4785056", "source_name": "Investing.com", "published_at": "2026-07-09T22:05:45", "published_display": "09 Jul 2026 22:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme (HALO) CEO sells 1,923 exercised shares under Rule 10b5-1 plan", "summary": "Halozyme Therapeutics President and CEO Helen Torley exercised options for 1,923 shares at $12.07 each and immediately sold them in open-market transactions between $79 and $80 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in Ma", "url": "https://www.stocktitan.net/sec-filings/HALO/form-4-halozyme-therapeutics-inc-insider-trading-activity-dbd58f1dbce4.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:05:44", "published_display": "09 Jul 2026 21:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics focuses on drug-delivery partnerships as investors watch Nasdaq biotech sentim", "summary": "Halozyme Therapeutics centers its growth strategy on developing drug-delivery collaborations with major pharmaceutical partners, focusing on turning hospital infusions into more convenient subcutaneous injections. The company generates revenue through milestones, royalties, and f", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/halozyme-therapeutics-focuses-on-drug-delivery-partnerships-as-investors/69725761", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T19:41:00", "published_display": "08 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) TD Cowen 45th Annual Healthcare Conference Summary", "summary": "Halozyme Therapeutics presented at the TD Cowen 45th Annual Healthcare Conference, focusing on its MHA patent portfolio for subcutaneous drug delivery, distinct from ENHANZE, and its licensing strategy, including potential litigation with Merck over Keytruda. The company highligh", "url": "https://quartr.com/events/halozyme-therapeutics-inc-halo-td-cowen-45th-annual-healthcare-conference_ofWrCUDq", "source_name": "Quartr", "published_at": "2026-07-08T16:39:26", "published_display": "08 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme signs collaboration deal with GSK for oncology targets", "summary": "Halozyme Therapeutics has entered into a global collaboration and license agreement with GSK to develop subcutaneous formulations of multiple oncology targets, including antibody drug conjugates, using Halozyme's ENHANZE drug delivery technology. The deal involves an upfront paym", "url": "https://www.investing.com/news/company-news/halozyme-signs-collaboration-deal-with-gsk-for-oncology-targets-93CH-4668120", "source_name": "Investing.com", "published_at": "2026-07-05T15:11:06", "published_display": "05 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme licenses Hypercon technology to Vertex for $15M", "summary": "Halozyme Therapeutics announced a global collaboration and license agreement with Vertex Pharmaceuticals, granting Vertex access to Halozyme's Hypercon technology for up to three drug targets in exchange for a $15 million upfront payment. Halozyme is also eligible for future mile", "url": "https://www.investing.com/news/company-news/halozyme-licenses-hypercon-technology-to-vertex-for-15m-93CH-4601077", "source_name": "Investing.com", "published_at": "2026-07-05T03:40:27", "published_display": "05 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued", "summary": "Halozyme Therapeutics (HALO) has undergone a leadership reshuffle, including a new President of Drug Delivery, coinciding with a 13.79% share price return in one month and a 47.13% return over the past year. While a narrative suggests the stock is 7.4% undervalued based on long-t", "url": "https://www.sahmcapital.com/news/content/halozyme-therapeutics-halo-leadership-reset-raises-the-question-of-whether-the-stock-is-fully-valued-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-04T15:39:40", "published_display": "04 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) COO Cortney Caudill to depart in management reshuffle", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNT3hrUlZkZkN0c0t1amtvNk1YMjFBN3JOTEdWUWxnTXdzN0JCQUJQYnJZWFAzM0hEeW90RnJoMGc2dGFBOWJ1VVBfc05aenJWWERzMFl1dkNqNGpaa1NvdXJrRzU0a3U4SW1QMFRfVnBTZm9NaUlfUUUwblN1a1F5YzZ0eDRLRnNQX1FuRXYxWnV1SXJFOU1mZl80b2pvRUs0YThGUjN6amphcHY0VnFnVy1kMVo?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme (NASDAQ: HALO) EVP receives new options, RSUs and RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPamFFUFNhZkthUG5rRE5aemVpSm5feGZfUGVfZ2U3Yl8zc0g5Y1pTbXZSV1VPQTlpR2RSb3RQUWY3OE5kYjBxcXcyZVV1TXV2WW5zRnhUSDRfWUJBVHR0RktFTVBjVnVCNVJpOHJZS3I3aFcxY3pBTGk2aXNFOHdMTXp6a2hneGJoZTJBWWVtQnFEQUVGdVdSNDg3NF9SSzFNNTl6MGNUQko0WjZ6QjY0LWwzc2VSaEdYd2kw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Appoints David Ramsay as President Drug Delivery", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/halozyme-appoints-david-ramsay-president-200200873.html", "source_name": "PR Newswire", "published_at": "2026-06-30T20:02:00+00:00", "published_display": "30 Jun 2026 20:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme taps former CFO Ramsay to lead drug delivery growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNSkxEWUdrQTVQWktuWGhHeW5MS1F5YU1nOTVabERNalI1R0Z2SVN2cjJ2dHl4T0pBajRRcDNvSUltbHk2UnBYcy1lX3RmZEV4VzA4WmM5MElVTWY0NGc2dVV1c0Q3ckxtOFo1Y1dyYU14SGxRbzYtdXNuQ05YQm9zR2h1QlI4R1ZVdGhsSUVPTmVvT2NpTGNJbnBldHU4N0hnbnA3VjlB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] HALOZYME THERAPEUTICS, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPVFZQOW1qOFNtYjZWbmdBdnBkbmRQRWEtMzJELWY3aFM0aVk1QlF5MUpER2c4TWZBUXpYRTJ4OFZEbWlQSHkxc1B3TDZCWlJrTXZuVVh0ZXp5UUVhX1QteUJIeThPSy1Ib2tRaFRTLXRNUXNRNS1kVEVUTlVPLUZESGxFU1d6blJVWmlzQVJjdFQwRElOZ1d3QUJtUmY4dllmbWhjbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics Stock Gains 5.2% on Analyst Buy Rating and argenx Data News - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxORG14c19CUmFsYTVGVEp1TmhoUzUzckhxWlZTM1FhdjNBbnhnN3cyNmwwQ3pTTlpTbUh4ZFdQV1FVaktuZk5LeUtGOU05eTFIUnFhXzdrZHBYNjVSZEoyc1ZMSmpWcldGRlVRYl9Dd1lhc2lQZUwxNWVUZjFFaDlMV3dWRE5zckNjOFdoMnY0SEdqbTEyYlY4RmdTaDMwWkl0N1h2aThRZEhjNG4zR2FqQ2cwdzh0eDl0Wmc1TTVSWEtDQ191elE?oc=5", "source_name": "IndexBox", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNVXJHNEl4ckN3QUtSR3pUdUNvbXo4VmZkUnd6Y2Vza0FVZGp6RUtPQVZFbUhkX192SzFFNkN4QTZCNmVlVjlzYTVMdFJNZTVhT3ltRktGRVVZNjlZdmFINDlMTUVlQUk2cmFsMm52OTVEMVR3NnVrUDIwbldwbmtJMXFPbVNibmRxdUxJd0M3RlFCLXE4azJVd0JBaTUtandaSEVvWDNEaUg?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Halozyme (NASDAQ: HALO) sells shares under Rule 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOY0FEUmRGSWlaYndGRzVJMmhSNWE3MUFVVW0zODJJR3pVaExvaEpqOC1TUVZzWWNmeFprYXVLcGwtQ3M0aGdwWmZ6eS1mQ05ma1FCX0xpM2tYVGRRQVVrQTVvOXRTLU1wanV4OGc5MEVvWm14T3RXREM3Z1VWYWtJQ2plWmF6YXJPTXlXUFg4V0xxOV9vOTI2Y2NFZ3FCMWVQcmU3ZjRmcGl1MXNMd210NHNoWVJ1M1pQeWtB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOMnZla1U3ejRxWXZNVEROdk1jNUdEei01MDlVR0xLaHR2Z1N3TTljNXYxd1A4M2pGRkVJbnFYb0c2MWktVG5zZXROd3dNS0hObm12UTFtSFZnZktpRS1aTHM2MHN2WG5pdVQzNEFIR1BDb0hqSXJmeHV4SUVVc0tNMWlxMzJyZFhiTVFXSERXa2VKSFZ4WFViYVp6TFkyT285TUFscC1Fc2NpYnEzSVJFQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics Q1 2026 Earnings Review | HALO Stock - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNTVJYZUd6S3hGS19GR3QyTFZYd2xObkkzMlRIN0xaVGxlbE9tdHIyM0E4bm1ERFFzXy1wdTdRTno4LWp3R2E0WnR5eVR3VWFRMmcyV3JHUUtvbUNKUGtUMXptdkhnS21UV2Z2Q1ZYcVM5eXdGeTZaaEhIU2hnZEdlMWJjaTBiRzI2R19MdU9oZw?oc=5", "source_name": "IndexBox", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Halozyme GSK ENHANZE Deal Adds Oncology ADC Royalty Upside Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPSktGWFZTemRxT0NYckpOM0xTa2JRT2Q3RzJfZGwybjNxSC1sYnZqNGh1ZmUtMWtNNjdLZkZWQ1pnX2xUWFV0Vzl5cjJHU0tPWUhqbi1aa1NXWE85MHpId3N3NmxUYUhWV1RoeG80Ui1HaDh6LVVvTk9VVC1wcE45SEZCSDg5RDZyVmRpMXgyTFZDU0FQSl9tUWowaE44amxmVS1NQ0FTM1pEUDBmV1RheV95SXMtZmlVRUpyTExTNDdyOVBzdU1OOTM2TzNLUmNkelQtR2xSMWRVRXdCTTFrRkdxWDQzLUN5U0RF0gHwAUFVX3lxTE1lM0NybEttTk45U1RUMENfanZLOXEtdnJfRmNpZ2tPNlBJUV96eWdwNXpRWXJGRHBPZS1CVWM3Vzg2TDhZQlU4SG5uZHVLNEQ2blN2TVFoTXhBTExaMlpsUEhrWkp3c3J5Y2Z3UHprcFZ3RTV1bXlKNlpaTnRFMVlESm5aMURRQXZRX2NyeXNjLU8wRUNPRjlEYmdGS0xHbk5QM1pQT3ZZVmxyd0VrTm4xM2haM3RBNzRXRWs0WTYtY2FfVDV3azUxa0YyX2cyOEE3Z1h2VG5SSENSb3BIX2otbWFzaHlldUFwUElHaWt2Zw?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka taps Halozyme tech to cut injection volume in psoriasis", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMmUxblhCY3hoQWY3cVl2MDJMVzB1Sk9nYWc5SElCQmROYzVMOUZJdFJDTTItdzNWT2RvYnBoendINzZFWV9CMHpTQjl0Nm14OGpxZmFvdGduOUN5S1ZpcW9FSC02M1lsUEhuZ0kwUkNJVy1hQUcwT2pxNkF0b29XdnlmOTJqaC1FazlHRE52UFFINWlGRE1VMXFORFNoLW9ySTZwVnpTMmRzTy0xUlppcFdLMk92dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Halozyme Therapeutics (HALO) After Its Recent Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTTA5YUZkUF9pSmZlNjJwUGtvXzlYaWNrbU1BYWtTSXhjaUg3MERDeHRnVFJNOUllNE5vdXVyazhPZkt4TEVMZTJVaExBcmYxX3NJOFpvZGotRmlJSU1HbVFpOTN1dWMyVVY0TFdhbDhNeWFyODhVQXJWSTZmNHNWbTJYN1JzbWlUQU5YalpLb2xBU1JWakdXMmQyNUtvWkc1Zk5ZTkREY2ZIZG1LQXZFZUZNYTN4MVFqcDJidUliSW1qbVF5WmZmd0VsTEQwVjN6WG12WDhGVEFPVWw4MHYwcFozRXlCLTBGS0JlQ9IB8gFBVV95cUxNdndfd0lLTjhiM3VmQzBMckd5Z2R1Y3paWldpMjFvS3BpQnk2ZllHX0EwLW8wdmM0ZndBLVRTdW9ZTVRXMDlmanNWUkVReU0tZG5XTXdtSWhteDYwWk01TWl0dlNhOUtacUdubDQ3SzFyYW1nRTYtbFA5OEVTNlRNeVhsUENmSXQ2OFBzcC0tRmw2TkhtQkJOTUlrZUtJT1lnaDBJZGlzU29Hc3dGa0c2NmtJS1BDelRYcmFROTM4MmtUNDF0RXJZTkpvbXdhVmtSYklSUkhWQXU0ZXFjRDZwT2lKVVRCTHJaRHA4a1dudDc3dw?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNNnJlVnhaeEJlMGJpay0wMWg4WDZaRW5iUE9Ob29LbUJvSE5TdTk2UXhramMtNVB3aW1fckM0UkdCSlZhRXdFbGgxRm5jdDdjcjlLSmk4Yjl0YU1peEZPVzFhU3JJcFVXRWZKY3VQdHZ2YWN6bEFMaEpYNUs2UXJRRVRoLXBEUkd2VVdUT09heE40MkpqODNrRWRydEluOXh4SENka2Y5QQ?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPWnRaTmI0WkpfN1Z1bjZxWkMxajkybTkyeHlkYjI5ZE40ZVIyekRBV1BraEVaQ3IwS0Z3R2k2U0tsQ3BGQnJ3cnR0MzNmQnQ0VjBRM3FYV0EyanNiVmdYV3NFNHNOVGdWZC1mdGxuNUFVLVZUamxOWVV6V0o4MWNoY0xFN0hHNDN0RjJGaDhlb19SeHpFc1VrWV8zbDVyb0t5MTFvTUpUV2VNLW1nRG1IbFl3?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Is Halozyme ENHANZE Deal Reshaping Subcutaneous Antibody Delivery For Incyte\u2019s Pipeline Strategy (INCY)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-21T20:26:04+00:00", "published_display": "21 Jul 2026 20:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Halozyme\u2019s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/did-halozyme-halo-incyte-enhanze-151039541.html", "source_name": "Simply Wall St.", "published_at": "2026-07-21T15:10:39+00:00", "published_display": "21 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com", "summary": "Benchmark reiterated its Buy rating and $90 price target for Halozyme Therapeutics following the company's licensing agreement with Incyte Pharmaceuticals. The deal involves Halozyme's Enhanze drug development technology to create subcutaneous formulations of Incyte's INCA033989.", "url": "https://ca.investing.com/news/stock-market-news/benchmark-reiterates-halozyme-stock-buy-rating-on-incyte-deal-93CH-4744464", "source_name": "Investing.com Canada", "published_at": "2026-07-21T14:10:37", "published_display": "21 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Incyte stock rating on Halozyme deal By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOSktKc1Y1WDI2MmUyam9OUnJZS3Jld1BodUxMR1pnZGtUN1JRUi1IeGFHeS1HTEFhOGQ1US1oczExcU02amVfZE00TmtxYVl6NWI1U0pDRkktV2lIdjZvaVRGdUx2d1dWUFdpTFhCNTZVeEhWRFFqaUdrY0FHdUdvbDlHNTlVM0NweUZrUkRjYXBOZlVmYndrOVQ1cUFjczl3WWVHTnh4T1RrT1RSaUhzaDJJbzFOYmhiUktIUzM1VQ?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-21T11:40:50+00:00", "published_display": "21 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme and Incyte sign licence agreement for INCA033989 formulations", "summary": "", "url": "https://finance.yahoo.com/m/471ceb81-68b7-373c-a767-a5d3eef4153b/halozyme-and-incyte-sign.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-21T09:31:32+00:00", "published_display": "21 Jul 2026 09:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued", "summary": "Halozyme Therapeutics recently partnered with Incyte, using its Enhanze technology for subcutaneous formulations. Despite a 12.46% share price increase over 30 days and long-term gains, the stock appears undervalued, with analysts estimating a fair value of $83.90 compared to its", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-halo/halozyme-therapeutics/news/halozyme-therapeutics-halo-lands-incyte-deal-on-a-valuation", "source_name": "Simply Wall Street", "published_at": "2026-07-21T10:10:37", "published_display": "21 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme (HALO) Partners with Incyte to Advance Drug Delivery Te", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPMmdtYk9PR2xieG9MdlRtcHJoZ3gtRHhIR1pMY0tuYXN1R1RsLTRCQ2dtOGRXYnBKSWVCc3JOaXRwZmJfNEpIdFdxTnp5cmMtaHM5Sk1JeU1fSy1NWXVYbUtySEFrSmZLNnNXNVVfR210Q1VLb3NCSjZXTENKVy0yVWM5Wi15TXNoc3E5M0I4R3RZRXlqOWJlT1hyTTRrY0l1VWNWdWRxdFp2TnBvNzRGb2Y5ZDFhQTQtbWxZZFdfcXBIOXZuVER6QWc4bnF0YVhBZll6MEFoLTRWamw3MTJJaWQ3MA?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-20T19:58:47+00:00", "published_display": "20 Jul 2026 19:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development", "summary": "Halozyme Therapeutics has entered into a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using its ENHANZE drug delivery technology. This agreement provides Halozyme with an upfront payment, potential milestone payments, a", "url": "https://finance.yahoo.com/healthcare/articles/halozyme-signs-enhanze-collaboration-incyte-150243781.html", "source_name": "Market source", "published_at": "2026-07-20T14:41:25", "published_display": "20 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Secures Global Deal with Incyte for Innovative Drug Delivery", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxPeU1FM1JLMi05MExiTlY1YXJhWlhWSEg4VFNrcko1b3FoTm9LM2ZDV1UwUXpvdDVKM1hqVEt6Smh6Vlg3c2RGRnU1SmRkdnJWSHgzWi1BN1dDTFpCZUFBbUZYdXpwQnRoQVdVTE5qenBaMkRJQWR2SURVdUFEdHc0azR1aDRZR3B3ZFlkM05kbFh4amppZi1iX01nUkwxdkZHOV9FZGY2Szl6TEZwemVfVkJ5MWR6Z2tUS19vc3B2X2dGcWpsYlBIZGZBdXhYRFlTeXY4X0hPbFI5Uk1BQ1gwNENZNDg4NzdITlVlZEhDTkhVVFJNenJLYmN3?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-20T13:05:06+00:00", "published_display": "20 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics, Incyte Sign Deal to Develop Subcutaneous Formulations of Blood Cancer Drug", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/halozyme-therapeutics-incyte-sign-deal-124534011.html", "source_name": "MT Newswires", "published_at": "2026-07-20T12:45:34+00:00", "published_display": "20 Jul 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme partners with Incyte on drug delivery technology By Investing.com", "summary": "Halozyme Therapeutics Inc. has announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE drug delivery technology. Halozyme will receive an upfront payment and is eligible for additional mileston", "url": "https://ca.investing.com/news/stock-market-news/halozyme-partners-with-incyte-on-drug-delivery-technology-93CH-4741809", "source_name": "Investing.com Canada", "published_at": "2026-07-20T12:41:25", "published_display": "20 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE\u00ae Technology", "summary": "Halozyme Therapeutics, Inc. (Nasdaq: HALO) has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE\u00ae drug delivery technology. This collaboration aims to improve the treatm", "url": "https://www.prnewswire.com/news-releases/halozyme-announces-global-collaboration-and-license-agreement-with-incyte-to-support-the-development-of-subcutaneous-formulations-of-inca033989-using-its-enhanze-technology-302829283.html", "source_name": "PR Newswire", "published_at": "2026-07-20T11:41:25", "published_display": "20 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to HALO Trends in Macro Strategies", "summary": "This article from Stock Traders Daily discusses technical reactions to HALO trends in macro strategies, focusing on Halozyme Therapeutics Inc. (NASDAQ: HALO). It highlights conflicting sentiment across different time horizons, suggesting choppy market conditions for the stock. Th", "url": "https://news.stocktradersdaily.com/news_release/23/Technical_Reactions_to_HALO_Trends_in_Macro_Strategies_071926041202_1784448722.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-19T04:13:10", "published_display": "19 Jul 2026 04:13", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival", "summary": "Halozyme Therapeutics (HALO) saw a positive impact from a partner trial for Darzalex Faspro, which uses Halozyme's ENHANZE technology. The trial reported significant survival benefits for multiple myeloma patients, highlighting the value of ENHANZE in improving established cancer", "url": "https://www.sahmcapital.com/news/content/halozyme-therapeutics-halo-gets-a-lift-as-darzalex-faspro-trial-improves-survival-2026-07-18", "source_name": "Sahm", "published_at": "2026-07-18T19:41:25", "published_display": "18 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Halozyme Therapeutics, Inc. Stocks", "summary": "This article lists various ETFs that include Halozyme Therapeutics, Inc. (HALO) stocks in their portfolios. The ETFs are sorted by their market value and provide details like weight, issuer, management style, expense ratio, and AUM, making it easier for investors to find opportun", "url": "https://www.tradingview.com/symbols/BOATS-HALO/etfs/", "source_name": "TradingView", "published_at": "2026-07-17T17:41:21", "published_display": "17 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxORmlQeURzMHhqdUNaSHBqMElOQ09hTnpGbTQ2N212dldMRlFib3IwaERwNUdFOWY1MUdUQ3NTUkFCWGhvb01WdXhFWGRZX0tZUi1jcHNfWlFTYWcyNUlsc1R6YnE0Q3JGSURxcXNNbVBrZ2k3YjVaXzJ1YzZXOW56WXZVeDF4ZENQMnhzYS1ZdmI2cU5QSnd6YTdYWUdBXzAyRkhVbGh5RDE?oc=5", "source_name": "Market source", "published_at": "2026-07-15T13:46:28+00:00", "published_display": "15 Jul 2026 13:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HALO5387960 Bond Risk Profile", "summary": "This article provides a risk profile for the Halozyme Therapeutics, Inc. 0.25% 01-MAR-2027 bond, identified as HALO5387960. It offers an overview of the bond's coupon, redemption details, and crucial risk assessment metrics. The content highlights credit risk, security level, inf", "url": "https://www.tradingview.com/symbols/FINRA-HALO5387960/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-15T06:12:46", "published_display": "15 Jul 2026 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HALO5387960 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides a coupon profile for the HALO5387960 bond, issued by Halozyme Therapeutics, Inc., detailing its interest rate and payment schedule. The bond has a current coupon rate of 0.25%, with the next payment planned for September 1, 2026. The article highlights the i", "url": "https://www.tradingview.com/symbols/FINRA-HALO5387960/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-14T22:40:49", "published_display": "14 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HALO5387960 Bond Profile \u2014 Key Metrics", "summary": "This article provides a bond profile for Halozyme Therapeutics, Inc.'s bond HALO5387960, detailing key metrics such as its 0.25% coupon rate and March 1, 2027 maturity date. It also includes information about the company, Halozyme Therapeutics, Inc., identifying it as a biopharma", "url": "https://www.tradingview.com/symbols/FINRA-HALO5387960/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T14:41:20", "published_display": "14 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 10% Upside Potential in the Biotech Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOcWVscy1sdVQ1SnZkbGpBMk5VbTkwczFmYTRqWmxaWkhsYkJHczlKYkcxYloweEpJa3Bxay1xMXRQUndmSS1feGQ0a05rUlcwazdjdTN2QU1zUTNGZ0hoU1JwNW15UnkwYzBtajVCb29SZ3ZtLWlvdUlRMEw4RnVodklVNWtqcm5YNnR3OFRMYXVxSnhjQ1VUU2hhbGotR1BsWVpnaFg0WXQ2LTJtTklrZnM1V2o2RERfcjE3VDA1Ynp2UEpkMzAyM0tSak5wYm5qVTIxOVZsV1J0am92LTdzMjdEN0o?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:18:25+00:00", "published_display": "13 Jul 2026 09:18", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Proxy filing Summary", "summary": "Halozyme Therapeutics (HALO) has released a summary of its proxy filing for the 2026 Annual Meeting, scheduled virtually for May 5, 2026. Key proposals include the election of two Class I directors, an advisory \"say-on-pay\" vote for executive compensation, and the ratification of", "url": "https://quartr.com/events/halozyme-therapeutics-halo-proxy-filing_ofWrSbzj", "source_name": "Quartr", "published_at": "2026-07-12T04:40:26", "published_display": "12 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) AGM 2026 Summary", "summary": "This article summarizes Halozyme Therapeutics' (HALO) 2026 Annual General Meeting (AGM), detailing the election of Class I directors, approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor. It also provides a brief overview of recent ", "url": "https://quartr.com/events/halozyme-therapeutics-halo-agm-2026_ofWrSfzP", "source_name": "Quartr", "published_at": "2026-07-11T18:11:32", "published_display": "11 Jul 2026 18:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Q1 2026 earnings summary", "summary": "Halozyme Therapeutics reported a strong Q1 2026 with total revenue increasing by 42% year-over-year to $376.7 million and net income up 27% to $150 million. The company announced a new $1 billion share repurchase program and expanded its ENHANZE and Hypercon platforms through new", "url": "https://quartr.com/events/halozyme-therapeutics-inc-halo-q1-2026_ofWrSUIm", "source_name": "Quartr", "published_at": "2026-07-11T16:41:02", "published_display": "11 Jul 2026 16:41", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Q1 2025 earnings summary", "summary": "Halozyme Therapeutics reported a strong Q1 2025, achieving 35% year-over-year revenue growth to $265 million and a 54% increase in net income to $118 million, driven by blockbuster products and new growth catalysts. The company also announced a $250 million share repurchase progr", "url": "https://quartr.com/events/halozyme-therapeutics-inc-halo-q1-2025_ofWrCl7j", "source_name": "Quartr", "published_at": "2026-07-11T08:39:25", "published_display": "11 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics, Inc. Stock 12\u2011Month Price Target Cut to $83.44, Implies 6% Upside", "summary": "Halozyme Therapeutics, Inc.'s average price target has been reduced from $83.9 to $83.44 by 9 analysts, with forecasts ranging from $57 to $96 per share. This new target implies a potential upside of approximately 6% based on the July 9 closing price. Despite the slight reduction", "url": "https://www.tradingview.com/news/tradingview:633e185273125:0-halozyme-therapeutics-inc-stock-12-month-price-target-cut-to-83-44-implies-6-upside/", "source_name": "TradingView", "published_at": "2026-07-10T07:11:10", "published_display": "10 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "2 Reasons to Like HALO and 1 to Stay Skeptical", "summary": "Halozyme Therapeutics (HALO) shows strong potential with impressive annualized revenue growth of 35.4% over five years and an excellent free cash flow margin averaging 46.2%. However, its adjusted operating margin significantly decreased by 35.1 percentage points in the last five", "url": "https://www.tradingview.com/news/stockstory:8d8c360f8094b:0-2-reasons-to-like-halo-and-1-to-stay-skeptical/", "source_name": "TradingView", "published_at": "2026-07-10T04:11:11", "published_display": "10 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Halozyme\u2019s Leadership Shake-Up Around Drug Delivery At Halozyme Therapeutics (HALO) Has Changed Its Investment Story", "summary": "Halozyme Therapeutics recently restructured its leadership, appointing David Ramsay as President of Drug Delivery and announcing the departure of COO Cortney Caudill. This move emphasizes the company's focus on its drug delivery franchise, particularly the ENHANZE platform, and a", "url": "https://www.sahmcapital.com/news/content/how-halozymes-leadership-shake-up-around-drug-delivery-at-halozyme-therapeutics-halo-has-changed-its-investment-story-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T04:10:26", "published_display": "10 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Halozyme Therapeutics Inc For: 9 July By Investing.com", "summary": "This article reports on the filing of Form 4 by Halozyme Therapeutics Inc., specifically for July 9. The headline and content confirm the filing, indicating standard regulatory disclosure within the financial markets. The brief notice was published on Investing.com.", "url": "https://za.investing.com/news/stock-market-news/form-4-halozyme-therapeutics-inc-for-9-july-93CH-4363437", "source_name": "Investing.com South Africa", "published_at": "2026-07-09T23:26:00", "published_display": "09 Jul 2026 23:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme president & CEO Helen Torley sells $153,390 in stock", "summary": "Helen Torley, President and CEO of Halozyme Therapeutics, Inc. (NASDAQ:HALO), sold 1,923 shares for $153,390 after exercising stock options. These transactions were conducted under a pre-arranged trading plan, and Torley now directly owns 767,780 shares. The company has also seen", "url": "https://www.investing.com/news/insider-trading-news/halozyme-president--ceo-helen-torley-sells-153390-in-stock-93CH-4785056", "source_name": "Investing.com", "published_at": "2026-07-09T22:05:45", "published_display": "09 Jul 2026 22:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme (HALO) CEO sells 1,923 exercised shares under Rule 10b5-1 plan", "summary": "Halozyme Therapeutics President and CEO Helen Torley exercised options for 1,923 shares at $12.07 each and immediately sold them in open-market transactions between $79 and $80 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in Ma", "url": "https://www.stocktitan.net/sec-filings/HALO/form-4-halozyme-therapeutics-inc-insider-trading-activity-dbd58f1dbce4.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:05:44", "published_display": "09 Jul 2026 21:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics focuses on drug-delivery partnerships as investors watch Nasdaq biotech sentim", "summary": "Halozyme Therapeutics centers its growth strategy on developing drug-delivery collaborations with major pharmaceutical partners, focusing on turning hospital infusions into more convenient subcutaneous injections. The company generates revenue through milestones, royalties, and f", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/halozyme-therapeutics-focuses-on-drug-delivery-partnerships-as-investors/69725761", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T19:41:00", "published_display": "08 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) TD Cowen 45th Annual Healthcare Conference Summary", "summary": "Halozyme Therapeutics presented at the TD Cowen 45th Annual Healthcare Conference, focusing on its MHA patent portfolio for subcutaneous drug delivery, distinct from ENHANZE, and its licensing strategy, including potential litigation with Merck over Keytruda. The company highligh", "url": "https://quartr.com/events/halozyme-therapeutics-inc-halo-td-cowen-45th-annual-healthcare-conference_ofWrCUDq", "source_name": "Quartr", "published_at": "2026-07-08T16:39:26", "published_display": "08 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme signs collaboration deal with GSK for oncology targets", "summary": "Halozyme Therapeutics has entered into a global collaboration and license agreement with GSK to develop subcutaneous formulations of multiple oncology targets, including antibody drug conjugates, using Halozyme's ENHANZE drug delivery technology. The deal involves an upfront paym", "url": "https://www.investing.com/news/company-news/halozyme-signs-collaboration-deal-with-gsk-for-oncology-targets-93CH-4668120", "source_name": "Investing.com", "published_at": "2026-07-05T15:11:06", "published_display": "05 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme licenses Hypercon technology to Vertex for $15M", "summary": "Halozyme Therapeutics announced a global collaboration and license agreement with Vertex Pharmaceuticals, granting Vertex access to Halozyme's Hypercon technology for up to three drug targets in exchange for a $15 million upfront payment. Halozyme is also eligible for future mile", "url": "https://www.investing.com/news/company-news/halozyme-licenses-hypercon-technology-to-vertex-for-15m-93CH-4601077", "source_name": "Investing.com", "published_at": "2026-07-05T03:40:27", "published_display": "05 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued", "summary": "Halozyme Therapeutics (HALO) has undergone a leadership reshuffle, including a new President of Drug Delivery, coinciding with a 13.79% share price return in one month and a 47.13% return over the past year. While a narrative suggests the stock is 7.4% undervalued based on long-t", "url": "https://www.sahmcapital.com/news/content/halozyme-therapeutics-halo-leadership-reset-raises-the-question-of-whether-the-stock-is-fully-valued-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-04T15:39:40", "published_display": "04 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) COO Cortney Caudill to depart in management reshuffle", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNT3hrUlZkZkN0c0t1amtvNk1YMjFBN3JOTEdWUWxnTXdzN0JCQUJQYnJZWFAzM0hEeW90RnJoMGc2dGFBOWJ1VVBfc05aenJWWERzMFl1dkNqNGpaa1NvdXJrRzU0a3U4SW1QMFRfVnBTZm9NaUlfUUUwblN1a1F5YzZ0eDRLRnNQX1FuRXYxWnV1SXJFOU1mZl80b2pvRUs0YThGUjN6amphcHY0VnFnVy1kMVo?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme (NASDAQ: HALO) EVP receives new options, RSUs and RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPamFFUFNhZkthUG5rRE5aemVpSm5feGZfUGVfZ2U3Yl8zc0g5Y1pTbXZSV1VPQTlpR2RSb3RQUWY3OE5kYjBxcXcyZVV1TXV2WW5zRnhUSDRfWUJBVHR0RktFTVBjVnVCNVJpOHJZS3I3aFcxY3pBTGk2aXNFOHdMTXp6a2hneGJoZTJBWWVtQnFEQUVGdVdSNDg3NF9SSzFNNTl6MGNUQko0WjZ6QjY0LWwzc2VSaEdYd2kw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Appoints David Ramsay as President Drug Delivery", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/halozyme-appoints-david-ramsay-president-200200873.html", "source_name": "PR Newswire", "published_at": "2026-06-30T20:02:00+00:00", "published_display": "30 Jun 2026 20:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme taps former CFO Ramsay to lead drug delivery growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNSkxEWUdrQTVQWktuWGhHeW5MS1F5YU1nOTVabERNalI1R0Z2SVN2cjJ2dHl4T0pBajRRcDNvSUltbHk2UnBYcy1lX3RmZEV4VzA4WmM5MElVTWY0NGc2dVV1c0Q3ckxtOFo1Y1dyYU14SGxRbzYtdXNuQ05YQm9zR2h1QlI4R1ZVdGhsSUVPTmVvT2NpTGNJbnBldHU4N0hnbnA3VjlB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] HALOZYME THERAPEUTICS, INC. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPVFZQOW1qOFNtYjZWbmdBdnBkbmRQRWEtMzJELWY3aFM0aVk1QlF5MUpER2c4TWZBUXpYRTJ4OFZEbWlQSHkxc1B3TDZCWlJrTXZuVVh0ZXp5UUVhX1QteUJIeThPSy1Ib2tRaFRTLXRNUXNRNS1kVEVUTlVPLUZESGxFU1d6blJVWmlzQVJjdFQwRElOZ1d3QUJtUmY4dllmbWhjbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics Stock Gains 5.2% on Analyst Buy Rating and argenx Data News - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxORG14c19CUmFsYTVGVEp1TmhoUzUzckhxWlZTM1FhdjNBbnhnN3cyNmwwQ3pTTlpTbUh4ZFdQV1FVaktuZk5LeUtGOU05eTFIUnFhXzdrZHBYNjVSZEoyc1ZMSmpWcldGRlVRYl9Dd1lhc2lQZUwxNWVUZjFFaDlMV3dWRE5zckNjOFdoMnY0SEdqbTEyYlY4RmdTaDMwWkl0N1h2aThRZEhjNG4zR2FqQ2cwdzh0eDl0Wmc1TTVSWEtDQ191elE?oc=5", "source_name": "IndexBox", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNVXJHNEl4ckN3QUtSR3pUdUNvbXo4VmZkUnd6Y2Vza0FVZGp6RUtPQVZFbUhkX192SzFFNkN4QTZCNmVlVjlzYTVMdFJNZTVhT3ltRktGRVVZNjlZdmFINDlMTUVlQUk2cmFsMm52OTVEMVR3NnVrUDIwbldwbmtJMXFPbVNibmRxdUxJd0M3RlFCLXE4azJVd0JBaTUtandaSEVvWDNEaUg?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Halozyme (NASDAQ: HALO) sells shares under Rule 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOY0FEUmRGSWlaYndGRzVJMmhSNWE3MUFVVW0zODJJR3pVaExvaEpqOC1TUVZzWWNmeFprYXVLcGwtQ3M0aGdwWmZ6eS1mQ05ma1FCX0xpM2tYVGRRQVVrQTVvOXRTLU1wanV4OGc5MEVvWm14T3RXREM3Z1VWYWtJQ2plWmF6YXJPTXlXUFg4V0xxOV9vOTI2Y2NFZ3FCMWVQcmU3ZjRmcGl1MXNMd210NHNoWVJ1M1pQeWtB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOMnZla1U3ejRxWXZNVEROdk1jNUdEei01MDlVR0xLaHR2Z1N3TTljNXYxd1A4M2pGRkVJbnFYb0c2MWktVG5zZXROd3dNS0hObm12UTFtSFZnZktpRS1aTHM2MHN2WG5pdVQzNEFIR1BDb0hqSXJmeHV4SUVVc0tNMWlxMzJyZFhiTVFXSERXa2VKSFZ4WFViYVp6TFkyT285TUFscC1Fc2NpYnEzSVJFQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics Q1 2026 Earnings Review | HALO Stock - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxNTVJYZUd6S3hGS19GR3QyTFZYd2xObkkzMlRIN0xaVGxlbE9tdHIyM0E4bm1ERFFzXy1wdTdRTno4LWp3R2E0WnR5eVR3VWFRMmcyV3JHUUtvbUNKUGtUMXptdkhnS21UV2Z2Q1ZYcVM5eXdGeTZaaEhIU2hnZEdlMWJjaTBiRzI2R19MdU9oZw?oc=5", "source_name": "IndexBox", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Halozyme GSK ENHANZE Deal Adds Oncology ADC Royalty Upside Potential", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oruka taps Halozyme tech to cut injection volume in psoriasis", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPMmUxblhCY3hoQWY3cVl2MDJMVzB1Sk9nYWc5SElCQmROYzVMOUZJdFJDTTItdzNWT2RvYnBoendINzZFWV9CMHpTQjl0Nm14OGpxZmFvdGduOUN5S1ZpcW9FSC02M1lsUEhuZ0kwUkNJVy1hQUcwT2pxNkF0b29XdnlmOTJqaC1FazlHRE52UFFINWlGRE1VMXFORFNoLW9ySTZwVnpTMmRzTy0xUlppcFdLMk92dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Halozyme Therapeutics (HALO) After Its Recent Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTTA5YUZkUF9pSmZlNjJwUGtvXzlYaWNrbU1BYWtTSXhjaUg3MERDeHRnVFJNOUllNE5vdXVyazhPZkt4TEVMZTJVaExBcmYxX3NJOFpvZGotRmlJSU1HbVFpOTN1dWMyVVY0TFdhbDhNeWFyODhVQXJWSTZmNHNWbTJYN1JzbWlUQU5YalpLb2xBU1JWakdXMmQyNUtvWkc1Zk5ZTkREY2ZIZG1LQXZFZUZNYTN4MVFqcDJidUliSW1qbVF5WmZmd0VsTEQwVjN6WG12WDhGVEFPVWw4MHYwcFozRXlCLTBGS0JlQ9IB8gFBVV95cUxNdndfd0lLTjhiM3VmQzBMckd5Z2R1Y3paWldpMjFvS3BpQnk2ZllHX0EwLW8wdmM0ZndBLVRTdW9ZTVRXMDlmanNWUkVReU0tZG5XTXdtSWhteDYwWk01TWl0dlNhOUtacUdubDQ3SzFyYW1nRTYtbFA5OEVTNlRNeVhsUENmSXQ2OFBzcC0tRmw2TkhtQkJOTUlrZUtJT1lnaDBJZGlzU29Hc3dGa0c2NmtJS1BDelRYcmFROTM4MmtUNDF0RXJZTkpvbXdhVmtSYklSUkhWQXU0ZXFjRDZwT2lKVVRCTHJaRHA4a1dudDc3dw?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Halozyme Therapeutics (HALO) One of the Most Undervalued Biotech Stocks to Buy Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNNnJlVnhaeEJlMGJpay0wMWg4WDZaRW5iUE9Ob29LbUJvSE5TdTk2UXhramMtNVB3aW1fckM0UkdCSlZhRXdFbGgxRm5jdDdjcjlLSmk4Yjl0YU1peEZPVzFhU3JJcFVXRWZKY3VQdHZ2YWN6bEFMaEpYNUs2UXJRRVRoLXBEUkd2VVdUT09heE40MkpqODNrRWRydEluOXh4SENka2Y5QQ?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPWnRaTmI0WkpfN1Z1bjZxWkMxajkybTkyeHlkYjI5ZE40ZVIyekRBV1BraEVaQ3IwS0Z3R2k2U0tsQ3BGQnJ3cnR0MzNmQnQ0VjBRM3FYV0EyanNiVmdYV3NFNHNOVGdWZC1mdGxuNUFVLVZUamxOWVV6V0o4MWNoY0xFN0hHNDN0RjJGaDhlb19SeHpFc1VrWV8zbDVyb0t5MTFvTUpUV2VNLW1nRG1IbFl3?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 105, "total_relevant": 63, "sentiment_summary": {"positive": 25, "negative": 4, "neutral": 34, "score": 58, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.6, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 8.11, "count": 17}, {"event": "deals", "label": "Deals and strategy", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 25, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 77.81, "latest_week": "2026-07-17", "one_week_move": 2.1, "four_week_move": 13.5, "twelve_week_move": 19.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.228232, "market_dynamics_buy_signal": false, "relative_strength": 0.935266, "fair_value_gap": 40.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.0466, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.1% over one week, +13.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "TradingView", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 6}, {"label": "Quartr", "count": 5}, {"label": "Investing.com Canada", "count": 3}, {"label": "Sahm", "count": 3}, {"label": "Investing.com", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 17}, {"label": "Deals and strategy", "count": 7}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.1% over one week, +13.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Is Halozyme ENHANZE Deal Reshaping Subcutaneous Antibody Delivery For Incyte\u2019s Pipeline Strategy (INCY)?"}], "updated_at": "2026-07-22T06:09:39.026513+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}